PE20121029A1 - Marcadores de riesgo para enfermedad cardiovascular - Google Patents

Marcadores de riesgo para enfermedad cardiovascular

Info

Publication number
PE20121029A1
PE20121029A1 PE2011002069A PE2011002069A PE20121029A1 PE 20121029 A1 PE20121029 A1 PE 20121029A1 PE 2011002069 A PE2011002069 A PE 2011002069A PE 2011002069 A PE2011002069 A PE 2011002069A PE 20121029 A1 PE20121029 A1 PE 20121029A1
Authority
PE
Peru
Prior art keywords
seq
subject
cardiovascular disease
sample
destined
Prior art date
Application number
PE2011002069A
Other languages
English (en)
Inventor
Perez-Rasilla Eduardo Salas
De La Iglesia Jaime Marrugat
Llanos Roberto Elousa
Fernandez Sergio Castillo
Gomez Joan Salgado
Munoz Jose Maria Ordovas
Original Assignee
Gendiag Exe Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gendiag Exe Sl filed Critical Gendiag Exe Sl
Publication of PE20121029A1 publication Critical patent/PE20121029A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

REFERIDA A UN PROCEDIMIENTO PARA DETERMINAR SI UN SUJETO PRESENTA UN RIESGO AUMENTADO DE PADECER UNA ENFERMEDAD O TRASTORNO CARDIOVASCULAR ADVERSO O PARA DETERMINAR LA RESPUESTA FRENTE A UNA TERAPIA CARDIOVASCULAR EN UN SUJETO QUE COMPRENDE LAS ETAPAS DE DTERMINAR, EN UNA MUESTRA AISLADA DE DICHO SUJETO, LA PRESENCIA DE POLIMORFISMOS EN LAS POSICIONES 27 DENTREO DE LAS SECUENCIAS ACIDOS NUCLEICOS DE LA SEC ID NO:1 A 11, EN EL QUE LA PRESENCIA DE UNA C EN LA POSICION 27 EN LA SEC ID NO: 1, DE A EN LA SEC ID NO:2, DE C EN LA SEC ID NO:3, DE T EN LA SEC ID NO:4, DE C EN LA SEC ID NO:5, DE A EN LA SEC ID NO:6, DE T EN LA SEC ID NO:7, DE C EN LA SEC ID NO:8, DE C EN LA SEC ID NO:9, DE T EN LA SEC ID NO:9, DE T EN LA SEC ID NO:10 Y DE T EN LA SEC ID NO:11 ES INDICATIVA DE UN RIESGO AUMENTADO DE PADECER UNA ENFERMEDAD CARDIOVASCULAR SELECCIONADA DE INFARTO DE MIOCARDIO, ANGINA DE PECHO, ATAQUES ISQUEMICOS, INSUFICIENCIA CARDIACA CONGESTIVA, ANEURISMA AORTICO, ENTRE OTROS O UNA COMBINACION DE LOS MISMOS. DICHA MUESTRA ES UN TEJIDO O MUESTRA DE TEJIDO ORAL, RASPADO O LAVADO O UNA MUESTRA BIOLOGICA, DE PREFERENCIA SALIVA, ORINA O SANGRE
PE2011002069A 2009-06-09 2010-06-09 Marcadores de riesgo para enfermedad cardiovascular PE20121029A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09162329.8A EP2264183B1 (en) 2009-06-09 2009-06-09 Risk markers for cardiovascular disease

Publications (1)

Publication Number Publication Date
PE20121029A1 true PE20121029A1 (es) 2012-08-09

Family

ID=41061079

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011002069A PE20121029A1 (es) 2009-06-09 2010-06-09 Marcadores de riesgo para enfermedad cardiovascular

Country Status (14)

Country Link
US (1) US9957565B2 (es)
EP (2) EP2264183B1 (es)
AR (1) AR077026A1 (es)
AU (1) AU2010257482B2 (es)
BR (1) BRPI1013082A2 (es)
CA (1) CA2764693C (es)
CL (1) CL2011003129A1 (es)
ES (2) ES2623633T3 (es)
MX (1) MX2011013243A (es)
PE (1) PE20121029A1 (es)
PT (2) PT2264183T (es)
RU (1) RU2524659C2 (es)
UY (1) UY32698A (es)
WO (1) WO2010142713A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
BR112012032537B8 (pt) 2010-07-09 2022-10-18 Somalogic Inc Métodos para diagnosticar se um indivíduo tem ou não câncer de pulmão de não pequenas células, ou para fornecer informações sobre câncer de pulmão de não pequenas células em um indivíduo
US20120040861A1 (en) 2010-08-13 2012-02-16 Somalogic, Inc. Pancreatic Cancer Biomarkers and Uses Thereof
HUE029534T2 (hu) * 2011-08-05 2017-02-28 Gendiag Exe Sl Genetikai markerek kardiovaszkuláris betegség kockázatának becslésére
CN114518458A (zh) * 2011-09-30 2022-05-20 私募蛋白质体运营有限公司 心血管危险事件预测及其用途
EP2843056B8 (en) * 2013-08-30 2019-06-26 GENINCODE UK, Ltd. Risk markers for cardiovascular disease in patients with chronic kidney disease
RU2547575C1 (ru) * 2014-02-06 2015-04-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ прогнозирования течения хронической сердечной недостаточности
RU2602451C1 (ru) * 2015-08-28 2016-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации Способ диагностики генетической предрасположенности к развитию ишемического инсульта у больных с фибрилляцией предсердий
EP3360067A4 (en) * 2015-10-07 2019-06-12 The Board Of Trustees Of The University Of the Leland Stanford Junior University PROCESS FOR DETERMINING WHETHER A PERSON IS INCLUDED IN AN ENSEMBLE FROM GENOMIC DATA
RU2624859C1 (ru) * 2016-06-15 2017-07-07 Общество с ограниченной ответственностью "Меднорд-Техника" (ООО "Меднорд-Техника") Способ оценки повышенного риска возникновения флеботромбозов у пациентов с ишемической болезнью сердца
CN106250524A (zh) * 2016-08-04 2016-12-21 浪潮软件集团有限公司 一种基于语义信息的机构名抽取方法和装置
US10451544B2 (en) 2016-10-11 2019-10-22 Genotox Laboratories Methods of characterizing a urine sample
WO2019191010A1 (en) * 2018-03-27 2019-10-03 Aardvark Therapeutics Inc. Personalized treatment method for congestive heart failure
US11308325B2 (en) * 2018-10-16 2022-04-19 Duke University Systems and methods for predicting real-time behavioral risks using everyday images
CN110229881A (zh) * 2019-07-03 2019-09-13 贵州省临床检验中心 一种与成人心血管疾病相关的snp分子标记及其应用
CN110229882A (zh) * 2019-07-03 2019-09-13 贵州省临床检验中心 一种与心血管疾病相关的mthfr基因分子标记及其应用
CN112210598A (zh) * 2019-07-11 2021-01-12 合肥中科普瑞昇生物医药科技有限公司 检测高血糖药物代谢相关基因多态性的引物组和试剂盒及它们的应用
CN110607360A (zh) * 2019-09-19 2019-12-24 华中科技大学同济医学院附属同济医院 一种评估慢性心力衰竭预后的引物组、试剂盒及评估慢性心力衰竭预后的方法
EP4132653A4 (en) * 2020-04-11 2024-05-22 Geneticure Inc. GENETIC METHOD FOR DIAGNOSIS AND TREATMENT OF PRE- AND POST-CORONAVIRUS INFECTIONS
US11610645B2 (en) * 2020-04-30 2023-03-21 Optum Services (Ireland) Limited Cross-variant polygenic predictive data analysis
US11482302B2 (en) 2020-04-30 2022-10-25 Optum Services (Ireland) Limited Cross-variant polygenic predictive data analysis
US11574738B2 (en) 2020-04-30 2023-02-07 Optum Services (Ireland) Limited Cross-variant polygenic predictive data analysis
US11978532B2 (en) 2020-04-30 2024-05-07 Optum Services (Ireland) Limited Cross-variant polygenic predictive data analysis
US11967430B2 (en) 2020-04-30 2024-04-23 Optum Services (Ireland) Limited Cross-variant polygenic predictive data analysis

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US723961A (en) 1902-10-01 1903-03-31 Nelson W Clark Lady's belt, collar, or the like.
US4883750A (en) 1984-12-13 1989-11-28 Applied Biosystems, Inc. Detection of specific sequences in nucleic acids
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5004565A (en) 1986-07-17 1991-04-02 The Board Of Governors Of Wayne State University Method and compositions providing enhanced chemiluminescence from 1,2-dioxetanes
US5856522A (en) 1995-05-04 1999-01-05 Tropix, Inc. Method of using synthesis of 1,2-dioxetanes and kits therefore
US5994073A (en) 1990-08-30 1999-11-30 Tropix, Inc. Enhancement of chemiluminescent assays
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6015880A (en) 1994-03-16 2000-01-18 California Institute Of Technology Method and substrate for performing multiple sequential reactions on a matrix
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5773628A (en) 1994-11-14 1998-06-30 Tropix, Inc. 1,2-dioxetane compounds with haloalkoxy groups, methods preparation and use
US5591591A (en) 1995-02-09 1997-01-07 Tropix, Inc. Dioxetane compounds for the chemiluminescent detection of proteases, methods of use and kits therefore
US5589136A (en) 1995-06-20 1996-12-31 Regents Of The University Of California Silicon-based sleeve devices for chemical reactions
US5679803A (en) 1995-10-25 1997-10-21 Tropix, Inc. 1,2 chemiluminescent dioxetanes of improved performance
US5885470A (en) 1997-04-14 1999-03-23 Caliper Technologies Corporation Controlled fluid transport in microfabricated polymeric substrates
US5800999A (en) 1996-12-16 1998-09-01 Tropix, Inc. Dioxetane-precursor-labeled probes and detection assays employing the same
JP4171075B2 (ja) 1997-04-25 2008-10-22 カリパー・ライフ・サイエンシズ・インコーポレーテッド 改良されたチャネル幾何学的形状を組み込む微小流体装置
US6159693A (en) 1998-03-13 2000-12-12 Promega Corporation Nucleic acid detection
WO2002072889A2 (en) 2001-01-12 2002-09-19 Applera Corporation Methods and compositions for microarray control
US20070015170A1 (en) * 2005-07-12 2007-01-18 Oy Jurilab Ltd Method and kit for detecting a risk of coronary heart disease
RU2322193C1 (ru) 2006-12-04 2008-04-20 Федеральное государственное учреждение "Учебно-научный медицинский центр" Управления делами Президента Российской Федерации Способ оценки генетического риска сердечно-сосудистых заболеваний у спортсменов
BRPI0807927A2 (pt) * 2007-02-21 2014-06-24 Decode Genetics Ehf Métodos para determinar uma susceptibilidade a doença cardiovascular em um indivíduo humano, de identificação de um marcador para uso para avaliar susceptibilidade a doença cardiovascular, para genotipar uma amostra de ácido nucleico, para avaliar um indivíduo para probabilidade de resposta a um agente terapêutico, para predizer prognóstico de um indivíduo diagnosticado com doença cardiovascular, e para monitorar progresso de tratamento de um indivíduo passando por tratamento para doença cardiovascular, kit para avaliar susceptibilidade a doença cardiovascular em um indivíduo humano, uso de uma sonda de oligonucleotídeo, meio legível por computador, e, aparelho para determinar um indicador genético para doença cardiovascular em um indivíduo humano
US7883851B2 (en) 2007-05-02 2011-02-08 Board Of Regents, The University Of Texas System Common allele on chromosome 9 associated with coronary heart disease

Also Published As

Publication number Publication date
EP2264183A1 (en) 2010-12-22
AU2010257482A1 (en) 2012-02-02
MX2011013243A (es) 2012-04-10
ES2623633T3 (es) 2017-07-11
EP2264183B1 (en) 2016-12-07
UY32698A (es) 2010-11-30
ES2627446T3 (es) 2017-07-28
AR077026A1 (es) 2011-07-27
CL2011003129A1 (es) 2012-04-27
PT2440674T (pt) 2017-05-23
BRPI1013082A2 (pt) 2016-07-26
EP2440674B1 (en) 2017-04-05
CA2764693C (en) 2017-07-11
CA2764693A1 (en) 2010-12-16
US20120141450A1 (en) 2012-06-07
RU2524659C2 (ru) 2014-07-27
EP2440674A1 (en) 2012-04-18
PT2264183T (pt) 2017-03-14
WO2010142713A1 (en) 2010-12-16
US9957565B2 (en) 2018-05-01
AU2010257482B2 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
PE20121029A1 (es) Marcadores de riesgo para enfermedad cardiovascular
Tyser et al. Calcium handling precedes cardiac differentiation to initiate the first heartbeat
CN104379740B (zh) 新型fgfr3融合体
Medioni et al. Expression of Slit and Robo genes in the developing mouse heart
Driscoll et al. Inflammatory and biomechanical drivers of endothelial-interstitial interactions in calcific aortic valve disease
Nollen et al. What is new in the Marfan syndrome?
EA200970781A1 (ru) Варианты генетической предрасположенности, связанные с сердечно-сосудистыми заболеваниями
NO20092530L (no) Genetiske markorer for risikohandtering av hjertearrytmi
Jakob et al. Piezo1 and BKCa channels in human atrial fibroblasts: Interplay and remodelling in atrial fibrillation
JP7079937B2 (ja) 肺血管疾患を治療するための組成物および方法
CY1116692T1 (el) Πυρρολοπυριδινες ως αναστολεις κινασης
CY1116178T1 (el) Αναστολεις των lox και loxl2 και χρησεις εξ' αυτων
ATE437965T1 (de) Doppelsträngige sonden zur fluoreszenzdetektion von nukleinsäuren
RU2021134325A (ru) Производные хинолина для лечения воспалительных заболеваний
WO2010007031A3 (en) Methods for improving cardiac differentiation of human embryonic stem cells
DE602006012995D1 (de) Brustkrebsdiagnoseverfahren
WO2008132763A3 (en) Genetic variants useful for risk assessment of coronary artery disease and myocardial infarction
AR088294A1 (es) Determinacion de polimorfismos de un nucleotido simple utiles para predecir la respuesta clinica al acetato de glatiramero
JP2015521475A5 (es)
RU2011127117A (ru) Способы и применения, включающие гемсвязывающий белок 1
JP2018500884A5 (es)
JP2007536913A5 (es)
ITNA20080006A1 (it) Proteine chimeriche capaci di formare particelle virus-like, che contengono sequenze peptidiche del beta-amiloide e la componente e2 della alfachetoacido deidrogenasi di "geobacillus stearothermophilus", utili per l'induzione di una risposta anticorp
CO6430477A2 (es) Sondas y cebadores para la deteccion de malaria
FR2930036B1 (fr) Procede de diagnostic d'une hypertension arterielle pulmonaire.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed